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Abstract 11 
Gastrointestinal bacterial infection represents a significant threat to human health, as well 12 
as a burden on food animal production and welfare. Although there is advanced knowledge 13 
about the molecular mechanisms underlying pathogenesis, including the development of 14 
immune responses to these pathogens, gaps in knowledge persist.  It is well established that 15 
gastrointestinal bacterial pathogens produce a myriad of proteins that affect the 16 
development and effectiveness of innate immune responses. However, relatively few 17 
proteins that directly affect lymphocytes responsible for humoral or cell-mediated immunity 18 
and memory have been identified. Here, we review factors produced by gastrointestinal 19 
bacterial pathogens that have direct T cell interactions and what is known about their 20 
functions and mechanisms of action. T cell interacting bacterial proteins that have been 21 
identified to date mainly target three major T cell responses: activation and expansion, 22 
chemotaxis or apoptosis. Further, the requirement for more focused studies to identify and 23 
understand additional mechanisms used by bacteria to directly affect the T cell immune 24 
response and how these may contribute to pathogenesis is highlighted. Increased 25 
knowledge in this area will help to drive development of better interventions in prevention 26 
and treatment of gastrointestinal bacterial infection. 27 
  28 
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Introduction 29 
Gastrointestinal bacterial infection represents a significant threat to human health 30 
and welfare, with an estimated 900 million illnesses resulting in over 500 000 deaths in a 31 
single year, according to the World Health Organisation (1). Although much is known about 32 
the molecular mechanisms underlying persistence, pathogenesis and protection, significant 33 
effort is still required to devise effective intervention strategies.  Bacterial immune evasion 34 
methods include expression of surface polysaccharides to resist complement-mediated 35 
killing and opsonisation, enzymes to detoxify reactive oxygen species in phagosomes, 36 
escape from phagosomes and in the case of intracellular bacterial pathogens, interference 37 
in cellular antigen-presentation and innate immune responses by proteins secreted by Type 38 
III or Type IV secretion systems (2).  The role of Type III secretion in gastrointestinal bacterial 39 
pathogens is covered by many high quality reviews (eg. 3), and therefore is not the focus of 40 
this review.  Relatively fewer mechanisms have been identified whereby bacteria are able to 41 
directly affect lymphocytes during infection.   Further, understanding the full role of these 42 
bacterial proteins and their T cell interactions during infections, any specificity for T cells 43 
subsets, and proof that they are able to directly meet T cells in the body is crucial to 44 
establish biological importance.  However, such evidence is often lacking, and a number of 45 
barriers to understanding these aspects exist.  46 
Here, we review the known molecules and strategies that contribute to the direct 47 
subversion or dampening of the adaptive T cell response in gastrointestinal bacterial 48 
infection.  In addition, we discuss the challenges and aspirations of identifying these 49 
mechanisms. 50 
 51 
T cell distribution in the intestine 52 
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An understanding of the importance of T-cell targeting strategies by bacteria that 53 
infect the intestine requires an understanding of the lymphoid architecture, distribution of 54 
gut resident T cells, the ability of T cells to be recruited to this tissue and the nature of the 55 
downstream immune response that is triggered upon infection.  T cell responses in the 56 
intestine are mainly governed by the gut-associated lymphoid tissue (GALT), which is similar 57 
to other secondary lymphoid tissues in the body, and in mammals, consists of the 58 
mesenteric lymph nodes (mLNs) and Peyer’s patches (PP), the appendix and multiple 59 
smaller isolated lymphoid follicles studding the intestinal wall. In addition, there are isolated 60 
immune cells scattered in the lamina propria (LP) and throughout the epithelium of the 61 
intestine (reviewed in 4) that contribute to intestinal immune responses (summarized in 62 
Figure 1). T cell responses in the gut can be initiated from several sites. Generally in an 63 
intestinal immune response, intravascular naïve T cells home to the GALT (specifically to the 64 
PP and mLN), where they can meet their cognate ligand in the context of the Major 65 
Histocompatibility Complex (MHC) and become activated.  These T cells are then able to exit 66 
the lymphoid tissue via the lymphatic vessels and enter the circulation to home back to the 67 
intestinal LP (reviewed in 5) where they are able to carry out their functions. Within the 68 
mucosa, dendritic cells in the LP sample antigens and migrate to the PP and mLN where they 69 
are able to prime and present antigen to naïve CD4+ and CD8+ T cells, which clonally 70 
expand. These T cells may become memory cells, which accumulate over time in the LP. The 71 
LP is mainly enriched for the CD4+ Treg and Th17 cells.  In contrast, the intraepithelial 72 
lymphocyte (IEL) resident T cell population is mainly composed of both T cell receptor (TCR) 73 
αβ and TCR γδ (TCR αβ are generally considered “conventional T cells”, TCR γδ cells are 74 
often considered non-conventional atypical T cells), both mainly CD8ββ isoform. However, 75 
IELs appear to lack some typical T cell surface molecules such as CD2 (adhesion molecule), 76 
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CD28 (activating co-receptor) and Thy-1 (pan T cell marker of human and mouse cells).  77 
These cells are considered “activated, yet resting” and are different compared to peripheral 78 
T cells (which express CD4 or CD8αβ isoform; reviewed in (4)).  79 
Although there is not a large literature describing direct effects of gastrointestinal 80 
bacterial pathogens on T cells, a picture of the general strategies used to alter T lymphocyte 81 
function is emerging (summarised in Figure 2).  The effects identified can be broadly 82 
assigned to three groups: those that affect T cell activation and proliferation, those that 83 
affect chemotaxis and those that cause elimination of T cells, with most of the strategies 84 
identified thus far falling into the first category.  Little duplication of specific strategies 85 
across species of intestinal bacteria has been identified so far, and the mechanisms and 86 
observations described are derived from a relatively small number of bacterial species. 87 
Proteins that affect T cell activation and proliferation 88 
A number of bacterial proteins have been identified that act to interfere with signalling 89 
cascades in T cell activation and expansion, which are outlined below. These proteins are 90 
often soluble, diffusible factors, and can act externally to the T cell, as well as intracellularly. 91 
Superantigens 92 
Perhaps the earliest, well known and characterised bacterial factor with T cell-93 
affecting activity is superantigen.  Barber observed superantigen activity in Staphylococcus 94 
in 1914, and  identified the cause to be a microorganism-derived toxin (6). Since then, there 95 
have been numerous studies characterising the activity of superantigens.  One of the 96 
hallmarks of superantigens is their ability to activate a large population of T cells at very low 97 
concentrations (7, 8). At a basic level, superantigens are able to cross-link  a relatively large 98 
number of T cells to antigen-presenting cells (APC)  compared to normal antigen-driven 99 
activation, inducing wide spread non-antigen-specific activation of T cells, ultimately leading 100 
 o
n
 January 22, 2018 by UNIVERSITY O
F EDINBURG
H
http://iai.asm
.org/
D
ow
nloaded from
 
6 
 
to clonal deletion and anergy, thus suppressing a productive T cell response (9).   101 
Superantigens are effective because they bind outside the peptide-binding groove of MHC, 102 
they are not MHC restricted and activation does not rely on antigen internalisation and 103 
processing.  In addition, they specifically require the TCR β chain, not the Vα-Vβ chain 104 
pairing required in conventional antigen recognition by the TCR (reviewed in 8).  105 
 Although most well described in Staphylococcus, superantigens have been identified 106 
in other bacteria, including the pathogens Yersinia enterocolitica (10), and Yersinia 107 
pseudotuberculosis (11), the latter of which most often causes a self-limiting gastrointestinal 108 
infection.  However, strains of Y. pseudotuberculosis have also been reported to infect the 109 
gut and cause Far East Scarlet-like Fever (reviewed in 16), and many strains associated with 110 
this pathogenic infection express the superantigen Y. pseudotuberculosis-derived mitogen A 111 
(YPMa). Strains deficient in YPMa have been demonstrated to have decreased 112 
pathogenicity, however, growth of the bacteria was unaffected in the major immune organs 113 
after oral infection, so YPMa may have more pronounced effects in systemic infection (13), 114 
and a more recent study has linked the toxic activity of YPMa to activation of a hepatotoxic 115 
CD4+ T cell subset (14). 116 
Lymphostatin 117 
Lymphostatin (LifA, Efa-1) is one of the largest known bacterial proteins at 365 kDa, 118 
and is a putative glycosyltransferase, expressed by enteropathogenic Escherichia coli (EPEC) 119 
and non-O157 enterohaemorrhagic E. coli (EHEC) (15).  It has homology to the large 120 
clostridial toxins A and B (TcdA/B) at the N terminal portion of the protein, where the 121 
catalytic glycosyltransferase domain of TcdA/B resides (15, 16).  The existence of a soluble 122 
factor capable of inhibiting mitogen-activated  lymphocyte proliferation and pro-123 
inflammatory cytokine expression was first described using crude bacterial lysates of the 124 
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prototype EPEC strain E3248/69 (17).  Lymphostatin was then subsequently identified using 125 
a cosmid library screen to identify the gene responsible for this activity, which was 126 
confirmed by mutation of the lifA gene in EPEC (15).  Recently, it was shown that 127 
lymphostatin, like its clostridial homologues, is able to bind sugar moieties, in this case UDP-128 
N-acetyl glucosamine (UDP-GlcNAc), and has significant predicted structural homology 129 
around the putative glycosyltransferase domain. A DXD motif within this domain is 130 
necessary for UDP-GlcNAc binding and lymphostatin activity, however, formal evidence of 131 
sugar transfer and the identity of the cellular target remain elusive (16).  It has been 132 
demonstrated that lymphostatin is capable of inhibiting all major T cell subsets.  In addition, 133 
lymphostatin has  some activity against B cells, but not natural killer cells (18).  Further, the 134 
effects of lymphostatin on T cells appear to be long-lived, even in the absence of continued 135 
incubation with the protein, preventing mitogenic activation for more than 18 hours after 136 
transient exposure and withdrawal of the protein. Lymphostatin was also able to inhibit 137 
antigen-specific proliferation of bovine T cells using Theileria parva antigens presented on 138 
infected irradiated APCs to T. parva specific T cells as a model antigen system (18). These 139 
findings suggest that lymphostatin might act to permanently de-sensitise T cells to stimulus, 140 
possibly suppressing T cell responses and preventing or dampening a productive immune 141 
response and delaying clearance of infection  (18). It would appear that the effects of 142 
lymphostatin interfere with signalling in a membrane proximal way, as inhibition was not 143 
achieved in T cells stimulated with Phorbol 12-myristate 13-acetate (PMA)/ionomycin, 144 
which bypass membrane signalling.  145 
Lymphostatin is known to play an important role in intestinal colonization of calves 146 
by non-O157 EHEC strains of multiple serogroups (19, 20) and of mice by Citrobacter 147 
rodentium (21). However, attenuation is evident early after infection, before adaptive 148 
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responses may be expected to have developed. Alongside the ability to suppress T cell 149 
activation, lymphostatin also appears to be associated with adhesion (22), possibly as a 150 
consequence of effects on Type III secretion in some strains (19, 20).  These results indicate 151 
that lymphostatin may have additional roles in infection.  There are a number of unresolved 152 
questions regarding the activity of lymphostatin, including its cellular target of glycosylation. 153 
Further, in O157:H7 strains of EHEC, where full-length lymphostatin is not expressed, there 154 
is a putative homologue, ToxB, that also shows T cell inhibitory activity, as well as homology 155 
at the N-terminal end of the molecule to TcdA/B (18). This suggests that lymphostatin and 156 
lymphostatin-like molecules may be a family of proteins expressed by E. coli to control T cell 157 
responses to infection. 158 
 159 
VacA 160 
Helicobacter pylori expresses the VacA vacuolating cytotoxin, which has direct 161 
activity against T cells, specifically inhibiting T cell proliferation (23–25) as well as effects on 162 
other cells, including phagocytes and epithelial cells (likely by a different mechanism; 163 
reviewed in 23). VacA is a two domain protein, processed from a protoxin form, after 164 
secretion via a Type Va system from the bacteria (reviewed in 24).  Variation in the VacA 165 
gene amongst different strains of H. pylori results in varying levels of toxicity among the 166 
different variants (28). Like other toxins, VacA must be taken up by the cell in order to exert 167 
its activity, and it has been shown that both domains are needed for proper uptake and 168 
function of the toxin (29). The integrin CD18, expressed on the cell surface, has been 169 
identified as being important for uptake of VacA in human T cells (30), mediated by Protein 170 
Kinase C (PKC), and activation of the T cell is required to see the active endocytosis of VacA 171 
in T cells (31). In addition, VacA is able to block calcium flux in the Jurkat T cell line (32), and 172 
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prevent IL-2 expression by blocking translocation of the transcription factor NF-AT (24, 25). 173 
Overall, the data suggest that VacA targets previously activated T cells. Using in vivo studies 174 
in mice,  a null mutation of vacA was reported to impair initial colonization of mice by H. 175 
pylori, however, once infection by the vacA mutant becomes established, the bacterial load 176 
and extent of intestinal inflammation were similar to the parent strain (33). This effect is 177 
independent of an effect on T cells, as mice T cells do not express a compatible receptor 178 
that allows uptake of VacA (30). 179 
 180 
YopH 181 
Another example of inhibition of T cell activation by interference in T cell signalling is 182 
the YopH protein from Yersinia. YopH is expressed by Yersinia spp. that infect the gut (34), 183 
including Y. entercolitica and Y. pseudotuberculosis, and has been characterised as a protein 184 
tyrosine phosphatase (35).  In in vitro studies, using T cell-like cell lines, YopH was able to 185 
inhibit IL-2 production induced by antigen stimulation, the effects of which were upstream 186 
of PMA/Ionomycin (36). It was apparent by Western Blotting that general tyrosine 187 
phosphorylation of signalling molecules was inhibited.  YopH has also been shown to exhibit 188 
activity against B cell activation via the B cell receptor, with similar characteristics (36). 189 
These effects were independently confirmed in primary human T cells (37).  In T cells,  YopH 190 
is able to dephosphorylate the early signalling molecule Lck (38).  Further, it has been shown 191 
that YopH interacts with a number of adaptor molecules involved in early T cell receptor 192 
signalling. Using a trapping mutant, YopH was shown to directly dephosphorylate 193 
recombinant phosphorylated Lck in an in vitro activity assay, while not 194 
dephosphosphorylating other associated adaptor molecules, indicating some specificity of 195 
activity (39). This is an elegant mechanism, as an effect on relatively few molecules of Lck 196 
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would have a large impact on downstream signalling due to amplification through the 197 
signalling cascade.  These studies remain quite far removed from the complex in vivo 198 
infection, so the implications of these activities are not entirely known. However, it has 199 
been demonstrated in vivo that yopH deficient Y. enterocolita are drastically attenuated in 200 
oral infection of C57BL/6 mice, although colonization of the small intestine persists until at 201 
least 21 days post-infection (40).  Colonization by the YopH mutant declined quickly after 202 
infection (40). Further, in an intranasal infection model, a yopH deficient strain was less 203 
effective at lung colonization (41). In both cases, reduced colonization was seen early in 204 
infection before one might expect an adaptive response to have properly formed, and so it 205 
remains unclear what role YopH/T cell interactions play in virulence. In addition to YopH, 206 
Yersinia expresses an additional protein, invasin, which may allow Yersinia to subvert 207 
lymphocytes, particularly T cells, to influence their motility and facilitate dissemination of 208 
Yersinia to distal sites (42).  These two proteins may function to simultaneously neutralize T 209 
cell activation while keeping the cells intact to allow Yersinia infection, and redirection to 210 
other sites within the body. An invasin homologue in EPEC and Citrobacter rodentium, 211 
intimin (reviewed in 41), has been shown to interact with T cells, however, it is difficult to 212 
separate its direct effects on lymphocytes from the vital role it plays in gut colonization 213 
when interpreting its role in vivo (44, 45). 214 
 215 
Interference with metabolic activity 216 
T cells undergo rapid metabolic reprogramming on activation, one of the 217 
requirements of which is a source extracellular amino acids (46).  Import of amino acids such 218 
as asparagine and glutamine is required to accommodate the increased metabolic load 219 
induced by aerobic glycolysis during activation and proliferation of T cells (47). There are at 220 
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least two examples of proteins from gastrointestinal bacterial pathogens that appear to 221 
inhibit T cell activation via limiting availability of extracellular amino acids. 222 
In a recent publication, Floch and colleagues (48) reported that the Campylobacter 223 
jejuni protein, gamma-glutamyl transpeptidase (GGT) was capable of inhibiting mitogenic 224 
proliferation of T cells in vitro.  Although GGT is known to be important in intestinal 225 
colonization by C. jejuni in the chicken (49), little is known about its activity on T cells. 226 
However, it is tempting to extrapolate from what is known about a similar GGT that is 227 
expressed by H. pylori. The GGT of H. pylori plays an essential role in colonization of the 228 
gastric mucosa in mice (50).  GGTs are N-terminal nucleophile hydrolases that play a role in 229 
the degradation of glutathione, and  GGTs across mammal and bacterial species often 230 
exhibit a high protein sequence identity, with the GGT of C. jejuni clustering with 231 
Helicobacter spp. (51).  Treatment of mouse T cells with recombinant GGT from H. suis 232 
inhibits CD3/CD28-stimulated proliferation in a concentration-dependent manner (52).  In 233 
human peripheral blood mononuclear cells, GGT also inhibits PMA/Ionomycin stimulated 234 
proliferation, causing cell cycle arrest, inhibiting c-Myc and c-Raf (53). GGT more specifically 235 
causes glutamine deprivation in the extracellular space of T cells, downregulating both c-236 
Myc and IRF4 which are sensitive to glutamine, and required for metabolic adaptation (54).  237 
Overall, the data suggest that GGT is able to modulate the response of T cells in infection, 238 
likely through control of the extracellular availability of glutamine, which is required during 239 
activation. 240 
A second example of a gastrointestinal bacterial protein that interferes with T cell 241 
metabolism comes from Salmonella enterica serovar Typhimurium, which has been 242 
reported to directly inhibit primary mouse T cells (55), and is thought to limit availability of 243 
asparagine to T cells (56).  When assessing a number of cell surface expressed molecules, no 244 
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difference was noted in levels of CD69, CD25α, CD44, and CD62L in cells infected with S. 245 
Typhimurium compared to uninfected controls. However, in the presence of S. 246 
Typhimurium, neither IL-2 nor IFN-γ were produced with CD3 cross-linking (both these 247 
cytokines are up-regulated during T cell activation).  Cytokine production was restored if the 248 
cells were separated from the bacteria in a transwell arrangement, indicating that direct 249 
contact with the bacteria was required for this effect.  From here, the authors extended 250 
their observations, again using in vitro methods with primary mouse cells, showing that S. 251 
Typhimurium was able to down regulate surface expression the TCR β chain, resulting in 252 
decreased gene expression, intracellular and surface protein, at least partially explaining the 253 
mechanism targeted to inhibit T cell activation (57).  Not only that, but this effect was only 254 
observed in the presence of live bacteria, as treatment with heat-inactivated bacteria 255 
abrogated this effect. The effects were shown to be unrelated to Type III secretion or the 256 
bacterial virulence plasmid.  It was later shown that the protein responsible for this was L-257 
asparaginase II (STM3106; asnB) (58). In a mouse model of bacterial persistence, the burden 258 
of bacteria was lower in mutants lacking L-asparaginase II, suggesting that this molecule 259 
may enable bacterial persistence by dampening the T cell-mediated immune response (58). 260 
In contrast, in a screen of S. Typhimurium mutants in pigs, calves and chickens, a transposon 261 
insertion was not  attenuating in the gut, albeit within 3-4 days after oral infection (59).  262 
Nonetheless, the characterization of the activity of the L-asparaginase II on T cells is a good 263 
example of how bacterial subversion can lead to insight into basic host cell biology. In this 264 
case these studies highlight the importance of asparagine as a nutrient in T cell metabolism 265 
and activation (60).   266 
 267 
Interference in lymphocyte chemotaxis   268 
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The majority of T cell-interacting bacterial proteins appear to mainly exert effects on 269 
T cell activation, however, another strategy is to interfere with lymphocyte migration.  For 270 
example, Shigella  exhibit the ability to directly invade T cells and cause an inhibition in their 271 
chemokine-induced migration (61).  S. flexneri are able to directly invade PMA-activated 272 
CD4+ T cells, but not unstimulated, unactivated, primary CD4+ cells, with substantially 273 
reduced responses to the chemoattractant CXCL12. CXCL12 signals through the chemokine 274 
receptor CXCR4, the expression of which was not perturbed in these experiments (61). The 275 
bacterial protein, IpgD, which can be secreted through the type III secretion apparatus (62), 276 
has been implicated as being responsible for this activity, by acting on the pool of 277 
intracellular phosphatidylinositol 4,5-bisphosphate (PIP2).  Additionally, it would appear 278 
that IpgD is able to act intracellularly in the absence of any other bacterial effectors (61). 279 
These observations have been verified experimentally in vivo in mice, revealing that S. 280 
flexneri target CD4+ T cells in the lymph node and confirming that invasion and migration 281 
arrest occur in vivo (63). This discrimination between activated and non-activated T cells 282 
could result in more specific targeting of activated T cells in the lamina propria rather than 283 
the lymphoid follicles in the intestinal mucosa, thus targeting those cells that might actively 284 
respond to infection. Further, a recent publication reported the ability of Shigella to inject 285 
effectors into T cells in the absence of subsequent invasion, and suggest that the majority of 286 
T cells are targeted by injection only, raising the possibility that the bacteria could use a “hit 287 
and run” strategy to affect lymphocytes (64). 288 
 289 
Elimination of T cells 290 
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A further strategy that is shared with more than one bacterial genus is seen with the 291 
induction of apoptosis in T cells by the heat labile toxins, expressed by E. coli and Vibrio 292 
cholerae, although they appear to have slightly different specificity and mode of action 293 
between families and variants of the toxin.  The heat labile toxins are structurally related 294 
bacterial toxins that induce diarrhea in humans and animals (65).  These toxins are 295 
oligomers consisting of an A polypeptide bound to a pentameric array of B polypeptides. 296 
The toxic effects are determined by the cell surface binding specificity of the B pentamers, 297 
and the ADP ribosylating specificity of the A subunit (66).  Cholera toxin (CT) produced by V. 298 
cholerae binds to the ganglioside GM1 on epithelial cells via its B subunits, and when it is 299 
trafficked to the cell cytosol, it catalyzes ADP ribosylation of adenylate cyclase, leading to 300 
increased intracellular cAMP causing water secretion and diarrhea (67).  However, it has 301 
additional effects on other cells, including T cells.  It was demonstrated some time ago that 302 
CT was able to induce apoptosis in CD8+ T cells, although at that time the implications 303 
during infection were unclear (68).  More recently, it was confirmed that CT was able to 304 
decrease the numbers of CD8 cells, and that this was not due to either a downregulation of 305 
cell surface receptors, or selective proliferation of other cell types (69).  Similarly, LTIIa from 306 
E. coli is also able to deplete CD8+ T cells, likely by induction of apoptosis via cross-linking of 307 
the ganglioside receptors, although this has not yet been explicitly demonstrated (69). In 308 
mice injected with LT, transient induction of apoptosis mediated by glucocorticoids was 309 
seen in all thymocyte subsets, although immature T cells were more affected than mature 310 
cells (70). This effect was dependent on route of administration,  and demonstrated that in 311 
vitro treatment of cells did not entirely reflect the in vivo effects observed (70).  In addition, 312 
the maturation state of the T cell appears to determine the mechanism of apoptosis 313 
triggered (71). Further, although CT does not appear to invoke apoptosis in CD4+ T cells, it 314 
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does appear to be able to inhibit activation, at least based on measurement of cell surface 315 
expressed molecules (69). 316 
There has been significant interest in using CT and LT as adjuvants in vaccination, and 317 
understanding how it is able to steer T cell responses provides insight in how to better 318 
improve vaccination, or to engineer non-toxic derivatives that are able to promote its 319 
adjuvancy (72–75).  320 
To our knowledge, there is only one other protein from a gastrointestinal bacterial 321 
pathogen reported to have the ability to invoke apoptosis in T cells. This is the YpkA protein 322 
of Yersinia, which is a multidomain protein with kinase activity.  Expression of YpkA from a 323 
mammalian expression vector transfected in Jurkat T cells induced significant apoptosis (76), 324 
however, its role during infection is unclear.    325 
 326 
Concluding remarks 327 
It is evident from the examples above that gastrointestinal bacterial pathogens have 328 
evolved diverse strategies to modulate lymphocyte function. However, the biological 329 
significance of such activity during infection remains challenging to dissect, particularly for 330 
factors that play additional roles in colonization. For such factors, the T lymphocyte 331 
response to infection by a null mutant relative to the isogenic parent will be affected by the 332 
magnitude and duration of exposure to bacterial antigens. One strategy to overcome this is 333 
to use ligated intestinal loop models and recover intraepithelial lymphocytes exposed to 334 
bacterial strains or their products in situ (e.g. (77)). Although, it can be challenging to 335 
stimulate such cells to proliferate ex vivo and loop models often hold large numbers of 336 
laboratory-cultured bacteria over the mucosa for a limited time, and thus do not simulate 337 
the normal progression of gastrointestinal infection. It is noteworthy that attenuation of 338 
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mutants lacking some lymphocyte inhibitory factors is detected before one may anticipate 339 
that adaptive responses have been generated, and further research is needed to understand 340 
their impact on early pro-inflammatory responses and lymphocyte migration in vivo.  341 
Further, for many of these proteins, little is known about their effects on T cells of specific 342 
subsets and differentiation states.  Knowledge of which might provide further insight into 343 
their impact and timing of action during infection. 344 
While some of the strategies outlined here rely on direct contact between the 345 
pathogen and lymphocytes (e.g. via Type III secretion), in many cases inhibition relies on 346 
diffusion of soluble proteins to meet their target cell type. Some of the factors described are 347 
active in extremely low concentrations (e.g. lymphostatin acts in the femtomolar range; 348 
(16)) and the extent to which lymphocytes in circulation are affected requires study. It is 349 
evident from the ability of Shiga toxins to cause endothelial damage in kidney glomeruli that 350 
proteins produced by gastrointestinal pathogens in the gut can act distally.  351 
While the molecular basis of the activity of some lymphocyte inhibitory factors is 352 
well understood (e.g. VacA, YopH, IpgD), for others a need exists to identify their cellular 353 
targets and how their modification produces the observed phenotype.  Such studies have 354 
the potential to yield novel insights into both the basis of pathogenesis, but also the cellular 355 
pathways and factors governing lymphocyte activation and function. With an understanding 356 
of the mode of action of inhibitory factors, it may also become feasible to design new 357 
treatments. For example, with the knowledge that Helicobacter may use γ-358 
glutamyltranspeptidase to restrict lymphocyte activation via interference in glutamate 359 
metabolism, researchers have recently demonstrated that oral glutathione supplementation 360 
 o
n
 January 22, 2018 by UNIVERSITY O
F EDINBURG
H
http://iai.asm
.org/
D
ow
nloaded from
 
17 
 
can reduce gastric pathology and inflammation due to H. suis in gerbils (78). The extent to 361 
which this is a consequence of altered T lymphocyte function requires further study.  362 
It is striking that relatively little direct duplication of strategies to inhibit lymphocyte 363 
function has been identified across bacterial genera. Nevertheless, the vast quantities of 364 
sequence data now generated for pathogens will facilitate the identification of homologs of 365 
lymphocyte inhibitory factors that may be relevant in other diseases and differ in 366 
mechanism. For example, a family of proteins homologous to lymphostatin occur in diverse 367 
Chlamydia species of veterinary and public health importance and share predicted 368 
glycosyltransferase motifs (79).  369 
In addition to evaluating the value of lymphocyte inhibitory factors as subunit 370 
vaccines or as targets for novel inhibitors, merit exists in exploring the therapeutic potential 371 
of such molecules for disorders associated with lymphocyte proliferation or activity. A 372 
challenge of such will be ensuring specific targeting of pathology-associated lymphocytes 373 
without deleterious effects on immune function.  374 
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FIGURE 1: GALT and T cell distribution in the intestine 381 
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Immune responses in the intestine are mainly controlled by gut associated lymphoid tissue 382 
(GALT), including the Peyers patches, mesenteric lymph nodes and isolated lymphoid 383 
follicles in the mucosa and lamina propria.  The mucosa is also studded with intraepithelial 384 
lymphocytes.  Naïve T cells can be recruited from the circulation to lymphoid organs in the 385 
intestines, where they can be activated. 386 
FIGURE 2: Summary of T cell interacting bacterial proteins and their targets  387 
The majority of bacterial proteins that interact with T cells are directed at modifying 388 
activation/proliferation, however, there are some proteins that affect chemotaxis and 389 
apoptosis.  Where the key affected molecules are known, these are indicated, however, the 390 
details of a number of molecules remain unknown. Bacterial protein names are bounded by 391 
gray boxes.  sAg= superantigen (Staphylococcus), CT= cholera toxin(Vibrio cholera), 392 
GGT=gamma glutamyl transferase (H. pylori, C. jejuni), IpgD= invasion plasmid gene D 393 
(Shigella), LifA= lymphocyte inhibiting factor A (E. coli),  LT= heat labile toxin (E. coli), 394 
STM3106=asparaginase (Salmonella), APC= antigen presenting cell, MHC= major 395 
histocompatibility complex. 396 
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